Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$8.8 million.

  • Akebia Therapeutics' Change in Account Payables fell 19116.09% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 76348.99%. This contributed to the annual value of -$1.4 million for FY2024, which is 7398.93% up from last year.
  • Akebia Therapeutics' Change in Account Payables amounted to -$8.8 million in Q3 2025, which was down 19116.09% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Account Payables ranged from a high of $18.9 million in Q4 2022 and a low of -$13.8 million during Q3 2021
  • Moreover, its 5-year median value for Change in Account Payables was -$2.2 million (2025), whereas its average is -$1.3 million.
  • Per our database at Business Quant, Akebia Therapeutics' Change in Account Payables plummeted by 27251.16% in 2021 and then skyrocketed by 49165.1% in 2022.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Change in Account Payables stood at $3.2 million in 2021, then skyrocketed by 491.65% to $18.9 million in 2022, then plummeted by 76.2% to $4.5 million in 2023, then tumbled by 46.84% to $2.4 million in 2024, then plummeted by 468.76% to -$8.8 million in 2025.
  • Its Change in Account Payables stands at -$8.8 million for Q3 2025, versus $3.7 million for Q2 2025 and -$2.2 million for Q1 2025.